For a patient with gastro‑oesophageal reflux disease, is there any difference in efficacy between capsule and tablet formulations of proton‑pump inhibitors?

Capsule vs Tablet Formulations: No Clinically Significant Difference for Standard GERD Treatment

For patients with GERD, there is no clinically meaningful difference in efficacy between capsule and tablet formulations of proton pump inhibitors—the choice should be based on patient-specific factors such as swallowing ability rather than expected therapeutic outcomes.

Key Evidence and Reasoning

The available guidelines do not distinguish between capsule and tablet formulations when recommending PPI therapy for GERD 1, 2. Both major AGA clinical practice updates from 2022-2023 recommend PPI therapy without specifying formulation type, indicating that standard formulations are considered therapeutically equivalent.

What Actually Matters for PPI Efficacy

The evidence shows that dosing frequency and timing are far more important than formulation type:

• Twice-daily PPI is superior to once-daily for gastric acid suppression and likely more effective for symptoms. In patients not responding to once-daily PPI, 54% improved after switching to twice-daily dosing 1
• A 4-8 week trial of single-dose PPI should be the initial approach, with escalation to twice daily if inadequate response 2
• Timing matters: PPIs should be taken before meals for optimal effect

Special Formulation Considerations

Orally disintegrating tablets (ODTs) may offer advantages for specific patient populations:

• Patients with dysphagia or odynophagia from severe erosive esophagitis benefit from ODTs, which dissolve on the tongue without water 3
• Geriatric and pediatric patients with swallowing difficulties show improved compliance with ODT formulations 3
• ODTs may provide faster onset through absorption from the mouth, throat, and upper esophagus 3

One study comparing different PPI formulations (lansoprazole ODT vs dexlansoprazole delayed-release capsule) found the dual delayed-release formulation more effective for atypical symptoms, but this was likely due to the dual-release mechanism rather than capsule vs tablet format 4.

Compounded vs Manufactured: No Difference

Research comparing compounded and manufactured omeprazole formulations found no statistical difference in intragastric or esophageal pH control, regardless of whether capsule or tablet form was used 5.

Clinical Algorithm

Choose formulation based on:

1. Standard GERD without swallowing issues: Any standard PPI formulation (capsule or tablet) is appropriate
2. Dysphagia/odynophagia present: Consider ODT formulation for improved compliance
3. Inadequate response: Escalate to twice-daily dosing rather than changing formulation type
4. Severe erosive esophagitis (LA grade C/D): Focus on potent acid suppression (vonoprazan if available, or standard PPI twice daily) rather than formulation type 6

Common Pitfalls to Avoid

• Don't assume capsules are more effective than tablets—no evidence supports this
• Don't switch formulations when patients fail therapy; instead, increase dosing frequency or confirm GERD diagnosis with objective testing 2
• Don't overlook timing: Taking PPIs before meals is more important than formulation choice
• Don't continue empiric PPI beyond 12 months without objective confirmation of GERD 2